Zobrazeno 1 - 10
of 2 126
pro vyhledávání: '"overall response"'
Autor:
Ning Yan, Shaohua Hu
Publikováno v:
BMC Psychiatry, Vol 24, Iss 1, Pp 1-10 (2024)
Abstract Objectives This study aims to evaluate the safety and efficacy of escitalopram and sertraline in post-stroke depression (PSD) patients, to provide more reliable therapeutics for cardiovascular and psychiatric clinical practice. Methods We re
Externí odkaz:
https://doaj.org/article/48febc8492e944fa9fbf640a4cc05c98
Autor:
Jimmy Belotte, Brunella Felicetti, Amanda J. Baines, Ahmed YoussefAgha, Luis Rojas-Espaillat, Ana Godoy Ortiz, Diane Provencher, Raúl Márquez Vázquez, Lucia González Cortijo, Xing Zeng
Publikováno v:
Trials, Vol 25, Iss 1, Pp 1-11 (2024)
Abstract Background Maintenance therapy with niraparib, a poly(ADP-ribose) polymerase inhibitor, has been shown to extend progression-free survival in patients with newly diagnosed advanced ovarian cancer who responded to first-line platinum-based ch
Externí odkaz:
https://doaj.org/article/6a0a2a80b0c94cb1a14431371e664115
Publikováno v:
BMC Medical Research Methodology, Vol 24, Iss 1, Pp 1-11 (2024)
Abstract Background The timing of treating cancer patients is an essential factor in the efficacy of treatment. So, patients who will not respond to current therapy should receive a different treatment as early as possible. Machine learning models ca
Externí odkaz:
https://doaj.org/article/8e1eef4fda3f48eabcf9f4dde45abdaf
Publikováno v:
Hematology, Vol 29, Iss 1 (2024)
ABSTRACTVenetoclax is a selective inhibitor of the anti-apoptotic protein B-cell lymphoma 2 (BCL2), as a targeted therapy for multiple myeloma (MM) patients. It was initially approved by the United States Food and Drug Administration for the treatmen
Externí odkaz:
https://doaj.org/article/9c59153d5af146aeb7865719eb56c1fe
Autor:
Caitlin Lazurko, Revital Linder, Kate Pulman, Genevieve Lennox, Tomer Feigenberg, Rouhi Fazelzad, Taymaa May, Tiffany Zigras
Publikováno v:
Current Oncology, Vol 30, Iss 9, Pp 8159-8171 (2023)
Serous epithelial ovarian cancer, classified as either high-grade (90%) or low-grade (10%), varies in molecular, histological, and clinicopathological presentation. Low-grade serous ovarian cancer (LGSOC) is a rare histologic subtype that lacks disea
Externí odkaz:
https://doaj.org/article/48278b6557e24405916fa8efc993d06c
Autor:
Arkadiusz Z. Dudek, MD, PhD, Min X. Xi, PhD, Katherine A. Scilla, MD, Hirva Mamdani, MD, Benjamin C. Creelan, MD, Andreas Saltos, MD, Tawee Tanvetyanon, MD, Alberto Chiappori, MD
Publikováno v:
JTO Clinical and Research Reports, Vol 4, Iss 12, Pp 100584- (2023)
Introduction: We hypothesized that ramucirumab could increase previously reported objective response rate (ORR) of 11% of single-agent nivolumab in the second-line therapy of unresectable mesothelioma. Methods: This was a cooperative group, single-ar
Externí odkaz:
https://doaj.org/article/0149c45692094f848ef9ee464ffa82d8
Publikováno v:
Hematology, Vol 28, Iss 1 (2023)
ABSTRACTBackground: Although multiple myeloma is still incurable, an abundance of novel treatments have become available for relapsed and or refractory multiple myeloma (RRMM). Direct head-to-head comparisons between the novel treatments are lacking.
Externí odkaz:
https://doaj.org/article/6775c56274aa4253b278a2df044eb262
Publikováno v:
Frontiers in Pharmacology, Vol 14 (2023)
Background: The role of body mass index (BMI) in the treatment outcomes of lymphoma patients is controversial. While investigating the efficacy of ABVD-like regimen in Hodgkin lymphoma (HL) patients, we observed that obese patients had poor responses
Externí odkaz:
https://doaj.org/article/6fa0e16190ee4decbb504ceca33c50e8
Autor:
S. S. Bessmeltsev, L. V. Stelmashenko, E. I. Podoltseva, E. V. Kariagina, G. N. Salogub, А. S. Nisamutdinova, L. M. Matuhina, K. M. Abdulkadyrov
Publikováno v:
Онкогематология, Vol 0, Iss 4, Pp 61-66 (2022)
Theproteasome inhibitor bortezomib (Velcade) has demonstrated clinical activity in patients with multiple myeloma (MM). We report the activity of borte-zomib plus dexamethasone in 60patients with relapsed and refractory myeloma. The patients had a me
Externí odkaz:
https://doaj.org/article/8553a7bdc296417c8a2e1b3fa806ced5
Autor:
Kosaka Y, Saeki T, Takano T, Aruga T, Yamashita T, Masuda N, Koibuchi Y, Osaki A, Watanabe J, Suzuki R
Publikováno v:
International Journal of Nanomedicine, Vol Volume 17, Pp 4567-4578 (2022)
Yoshimasa Kosaka,1– 3 Toshiaki Saeki,2 Toshimi Takano,4,5 Tomoyuki Aruga,6 Toshinari Yamashita,7 Norikazu Masuda,8,9 Yukio Koibuchi,10 Akihiko Osaki,2 Junichiro Watanabe,11,12 Ryu Suzuki13 1Department of Breast and Endocrine Surgery, Kitasato Unive
Externí odkaz:
https://doaj.org/article/48450fdc211e4d19b0d9bff9431eb010